Role of ketamine in treatment-resistant depression
Journal of Education Health and Sport April 5, 2025 Joanna Dmochowska, Marcin Ciechański, Joanna Cieszkowska et al. 1 citation
Introduction: Depression, affecting 350 million people globally, is a leading cause of disability. Common symptoms include low mood, sadness, guilt, anxiety, and suicidalthoughts. Current treatments, mostly monoamine-based antidepressants, have limitations such as delayed effects and low efficacy, with over 60% of patients not achieving lasting remission. Ketamine, an NMDA antagonist, has shown...